Silexion Therapeutics Corp financial data

Symbol
SLXN, SLXNW on Nasdaq
Location
12 Abba Hillel Road, Ramat Gan, Israel
Fiscal year end
December 31
Latest financial report
8-K - Q4 2024 - Aug 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 157 %
Debt-to-equity -442 %
Return On Equity 1.22K %
Return On Assets -356 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 732K shares
Common Stock, Shares, Outstanding 580K shares +164%
Common Stock, Value, Issued 8K USD +700%
Weighted Average Number of Shares Outstanding, Basic 580K shares +7687%
Weighted Average Number of Shares Outstanding, Diluted 580K shares +7687%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.7M USD +32.9%
General and Administrative Expense 8.17M USD +105%
Operating Income (Loss) -13.9M USD -64.9%
Nonoperating Income (Expense) 3.97M USD +112%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -17.8M USD -68.1%
Income Tax Expense (Benefit) 3K USD +50%
Net Income (Loss) Attributable to Parent -17.8M USD -68.1%
Earnings Per Share, Basic 189 USD/shares -97.8%
Earnings Per Share, Diluted 189 USD/shares -97.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.47M USD +104%
Other Assets, Current 63K USD -4.55%
Assets, Current 5.24M USD +126%
Property, Plant and Equipment, Net 30K USD -25%
Operating Lease, Right-of-Use Asset 472K USD +237%
Assets 5.8M USD +150%
Accounts Payable, Current 692K USD +146%
Employee-related Liabilities, Current 628K USD +150%
Liabilities, Current 2.15M USD -9.05%
Operating Lease, Liability, Noncurrent 337K USD +4113%
Liabilities 5.68M USD +139%
Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value 0 USD -100%
Retained Earnings (Accumulated Deficit) -47.5M USD -60.1%
Stockholders' Equity Attributable to Parent 120K USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 120K USD -21.6%
Liabilities and Equity 5.8M USD +130%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.5M USD -135%
Net Cash Provided by (Used in) Financing Activities -195K USD
Net Cash Provided by (Used in) Investing Activities -23K USD
Common Stock, Shares Authorized 1.48M shares -54.8%
Common Stock, Shares, Issued 580K shares +131%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.54M USD +103%
Interest Paid, Excluding Capitalized Interest, Operating Activities 40K USD
Deferred Tax Assets, Valuation Allowance 6.9M USD +25.3%
Deferred Tax Assets, Gross 7.02M USD +26.4%
Operating Lease, Liability 526K USD +208%
Depreciation 17K USD -57.1%
Payments to Acquire Property, Plant, and Equipment 23K USD
Lessee, Operating Lease, Liability, to be Paid 636K USD
Property, Plant and Equipment, Gross 99K USD -25.6%
Operating Lease, Liability, Current 171K USD +58.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 167K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 165K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure -7.88%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 110K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 172K USD
Deferred Tax Assets, Operating Loss Carryforwards 5.8M USD +31.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 132K USD
Operating Lease, Payments 56K USD
Additional Paid in Capital 47.6M USD +318%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 5.86M USD +15.6%